UK Biobank, the world’s most significant source of data and biological samples for health research, is set to receive £127.6m to fund a move to a purpose-built facility at Bruntwood SciTech’s Manchester Science Park.
This follows an application by the Medical Research Council to the UK Research and Innovation (UKRI) Infrastructure Fund to support UK Biobank’s development.
UK Biobank’s biological samples, laboratories, headquarters and around half of its 250 staff will move to the new facility. The funding will cover a latest-generation robotic freezer that stores and retrieves 20 million biological samples that have been donated by UK Biobank’s 500,000 volunteer participants.
The facility will enable new projects to turn the samples into data and drive discoveries into how to prevent and treat a wide range of diseases.
With the support of the University of Manchester, Bruntwood SciTech – one of the UK’s leading property developers dedicated to the growth of the science and technology sector – is developing the new 131,000 sq ft Greenheys facility within Manchester Science Park, which sits at the heart of the city’s Oxford Road Corridor innovation district.
Professor Dame Nancy Rothwell, president and vice-chancellor of the University of Manchester and member of UK Biobank’s board, said: “I’m very pleased that UK Biobank has chosen to move here as it is yet more evidence of how Manchester has become one of the world’s leading hubs for science and innovation.
“UK Biobank will be joining the community of stellar research organisations that are already working with the University of Manchester to make a difference across the UK and around the world.”
Professor Dame Ottoline Leyser, CEO of UKRI, said: “UKRI is proud to invest in cutting-edge infrastructure across the UK to drive discovery, strengthen innovative businesses and improve public services, creating a wide range of high-quality jobs.
“UK Biobank is one of the UK’s leading biomedical science infrastructures, providing essential resources for thousands of academic and industry projects in the UK and around the world. Demand is growing year-on-year as UK Biobank’s datasets get richer over time.
“The insights enabled by UK Biobank have already driven change in the NHS and we look forward to seeing this powerful resource continue to thrive.”
Kath Mackay, director of life sciences at Bruntwood SciTech, said: “Manchester is a world-renowned hub for science and technology, and the ability for UK Biobank to grow here is testament to the quality of talent, innovation and support within the city.
“The development of Greenheys represents the third phase of our masterplan to grow Manchester Science Park to more than 1 million sq ft of cutting-edge life sciences and tech space which, critically, will support the creation of over 2,500 jobs as Manchester’s Oxford Road Corridor continues to thrive.”
Relocation to the Greenheys site on Manchester Science Park will provide UK Biobank with new opportunities for collaboration with multi-disciplinary researchers and industry.
It will also offer access to additional talent due to the proximity to leading institutions operating across research, academia, business and the NHS.
The move will also support the Government’s ambitions stated in the ‘Levelling Up’ White Paper to increase R&D spending outside the Greater Southeast by over 40% by 2030, whilst retaining UK Biobank in the Greater Manchester area and contributing to the advancement of one of the UK’s most established life science and tech communities.